72 related articles for article (PubMed ID: 19538804)
1. Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis.
Paddison JS; Temel JS; Fricchione GL; Pirl WF
Palliat Support Care; 2009 Jun; 7(2):213-7. PubMed ID: 19538804
[TBL] [Abstract][Full Text] [Related]
2. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer.
Brown DJ; McMillan DC; Milroy R
Cancer; 2005 Jan; 103(2):377-82. PubMed ID: 15558809
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
Teramukai S; Kitano T; Kishida Y; Kawahara M; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Furuse K; Fukushima M
Eur J Cancer; 2009 Jul; 45(11):1950-8. PubMed ID: 19231158
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
5. Fatigue during breast radiotherapy and its relationship to biological factors.
Wratten C; Kilmurray J; Nash S; Seldon M; Hamilton CS; O'Brien PC; Denham JW
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):160-7. PubMed ID: 15093912
[TBL] [Abstract][Full Text] [Related]
6. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
7. Activated changes of platelet ultra microstructure and plasma granule membrane protein 140 in patients with non-small cell lung cancer.
Zhuge Y; Zhou JY; Yang GD; Zu DL; Xu XL; Tian MQ; Lu GH
Chin Med J (Engl); 2009 May; 122(9):1026-31. PubMed ID: 19493436
[TBL] [Abstract][Full Text] [Related]
8. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
9. Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Llanillo M; Sánchez-Yagüe J
Exp Mol Pathol; 2009 Dec; 87(3):226-33. PubMed ID: 19733167
[TBL] [Abstract][Full Text] [Related]
10. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
Masago K; Fujita S; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Ichikawa M; Mio T; Mishima M
Cancer Sci; 2009 Oct; 100(10):1917-22. PubMed ID: 19594543
[TBL] [Abstract][Full Text] [Related]
11. Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis.
Cameron P; Ellis PM; Pond GR; Goffin JR
Palliat Med; 2012 Sep; 26(6):797-803. PubMed ID: 21844136
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
13. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
[TBL] [Abstract][Full Text] [Related]
14. Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer.
Yang HX; Hou X; Lin P; Rong TH; Yang H; Fu JH
Ann Thorac Surg; 2009 Aug; 88(2):372-8. PubMed ID: 19632375
[TBL] [Abstract][Full Text] [Related]
15. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review.
Schubert C; Hong S; Natarajan L; Mills PJ; Dimsdale JE
Brain Behav Immun; 2007 May; 21(4):413-27. PubMed ID: 17178209
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
17. Modafinil for the treatment of fatigue in lung cancer: a pilot study.
Spathis A; Dhillan R; Booden D; Forbes K; Vrotsou K; Fife K
Palliat Med; 2009 Jun; 23(4):325-31. PubMed ID: 19270033
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with true pathologic stage I non-small cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2009 Sep; 88(3):917-22; discussion 922-3. PubMed ID: 19699920
[TBL] [Abstract][Full Text] [Related]
19. Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer.
Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Anticancer Res; 2009 Jul; 29(7):2687-90. PubMed ID: 19596947
[TBL] [Abstract][Full Text] [Related]
20. Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection?
Ratto GB; Costa R; Maineri P; Alloisio A; Bruzzi P; Dozin B
J Thorac Cardiovasc Surg; 2009 Oct; 138(4):849-58. PubMed ID: 19660370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
